---
title: "Cipla's Virgonagar, India Unit Gets 'Voluntary Action Indicated' Classification in US FDA Inspection"
date: "2025-02-10 09:48:31"
summary: "Cipla said the US Food and Drug Administration (USFDA) has classified the inspection of its manufacturing facility at Virgonagar, Bengaluru, India, as \"Voluntary Action Indicated,\" according to a Saturday filing to the Indian stock exchanges. The US FDA had conducted a routine current Good Manufacturing Practice inspection at the pharmaceutical..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Cipla said the US Food and Drug Administration (USFDA) has classified the inspection of its manufacturing facility at Virgonagar, Bengaluru, India, as "Voluntary Action Indicated," according to a Saturday filing to the Indian stock exchanges.

The US FDA had conducted a routine current Good Manufacturing Practice inspection at the pharmaceutical manufacturer's Virgonagar unit between Nov. 7, 2024, and Nov. 13, 2024.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250209:G2465335:0/)
